⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PHAR News
Pharming Group N.V. ADS, each representing 10 ordinary shares
Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026
globenewswire.com
PHAR
Pharming announces CEO transition
globenewswire.com
PHAR
Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS
globenewswire.com
PHAR
Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026
globenewswire.com
PHAR
FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.
globenewswire.com
PHAR
Pharming Group to participate in September investor conferences
globenewswire.com
PHAR
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Bronstein, Gewirtz & Grossman, LLC (PHAR) And Encourages Stockholders to Reach Out
accessnewswire.com
PHAR
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pharming Group N.V. (PHAR) And Encourages Shareholders to Connect
accessnewswire.com
PHAR
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pharming Group N.V. (PHAR) And Encourages Shareholders to Reach Out
accessnewswire.com
PHAR
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pharming Group N.V. (PHAR) and Encourages Shareholders to Learn More About the Investigation
accessnewswire.com
PHAR